Oncolytics Biotech Inc - Asset Resilience Ratio
Oncolytics Biotech Inc (ONC) has an Asset Resilience Ratio of 83.86% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ONC current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2024)
This chart shows how Oncolytics Biotech Inc's Asset Resilience Ratio has changed over time. See ONC net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Oncolytics Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Oncolytics Biotech Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$2.71 Million | 13.75% |
| Short-term Investments | CA$13.81 Million | 70.11% |
| Total Liquid Assets | CA$16.52 Million | 83.86% |
Asset Resilience Insights
- Very High Liquidity: Oncolytics Biotech Inc maintains exceptional liquid asset reserves at 83.86% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Oncolytics Biotech Inc Industry Peers by Asset Resilience Ratio
Compare Oncolytics Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Oncolytics Biotech Inc (2003–2024)
The table below shows the annual Asset Resilience Ratio data for Oncolytics Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 83.83% | CA$16.92 Million ≈ $12.24 Million |
CA$20.19 Million ≈ $14.60 Million |
+66.42pp |
| 2023-12-31 | 17.40% | CA$6.76 Million ≈ $4.89 Million |
CA$38.82 Million ≈ $28.08 Million |
-68.68pp |
| 2022-12-31 | 86.08% | CA$32.14 Million ≈ $23.25 Million |
CA$37.33 Million ≈ $27.01 Million |
+80.15pp |
| 2021-12-31 | 5.93% | CA$2.72 Million ≈ $1.97 Million |
CA$45.88 Million ≈ $33.19 Million |
-84.97pp |
| 2020-12-31 | 90.90% | CA$31.22 Million ≈ $22.58 Million |
CA$34.35 Million ≈ $24.85 Million |
+18.93pp |
| 2019-12-31 | 71.97% | CA$14.15 Million ≈ $10.23 Million |
CA$19.66 Million ≈ $14.22 Million |
-20.19pp |
| 2018-12-31 | 92.16% | CA$13.70 Million ≈ $9.91 Million |
CA$14.87 Million ≈ $10.75 Million |
+26.95pp |
| 2017-12-31 | 65.21% | CA$11.84 Million ≈ $8.56 Million |
CA$18.15 Million ≈ $13.13 Million |
+41.88pp |
| 2016-12-31 | 23.33% | CA$3.44 Million ≈ $2.49 Million |
CA$14.76 Million ≈ $10.68 Million |
+15.80pp |
| 2015-12-31 | 7.53% | CA$2.06 Million ≈ $1.49 Million |
CA$27.38 Million ≈ $19.81 Million |
-4.29pp |
| 2014-12-31 | 11.82% | CA$2.03 Million ≈ $1.47 Million |
CA$17.19 Million ≈ $12.44 Million |
+4.72pp |
| 2013-12-31 | 7.09% | CA$2.00 Million ≈ $1.45 Million |
CA$28.22 Million ≈ $20.42 Million |
-1.83pp |
| 2012-12-31 | 8.92% | CA$1.97 Million ≈ $1.42 Million |
CA$22.08 Million ≈ $15.97 Million |
+3.54pp |
| 2011-12-31 | 5.38% | CA$1.94 Million ≈ $1.40 Million |
CA$36.02 Million ≈ $26.06 Million |
-2.75pp |
| 2010-12-31 | 8.12% | CA$3.61 Million ≈ $2.61 Million |
CA$44.43 Million ≈ $32.14 Million |
+3.40pp |
| 2009-12-31 | 4.72% | CA$1.76 Million ≈ $1.27 Million |
CA$37.27 Million ≈ $26.96 Million |
-37.08pp |
| 2008-12-31 | 41.80% | CA$5.85 Million ≈ $4.23 Million |
CA$13.99 Million ≈ $10.12 Million |
-18.30pp |
| 2007-12-31 | 60.10% | CA$18.50 Million ≈ $13.38 Million |
CA$30.78 Million ≈ $22.27 Million |
-11.77pp |
| 2006-12-31 | 71.87% | CA$24.12 Million ≈ $17.45 Million |
CA$33.57 Million ≈ $24.28 Million |
-7.83pp |
| 2005-12-31 | 79.70% | CA$36.89 Million ≈ $26.69 Million |
CA$46.29 Million ≈ $33.49 Million |
+25.22pp |
| 2004-12-31 | 54.47% | CA$21.51 Million ≈ $15.56 Million |
CA$39.49 Million ≈ $28.57 Million |
-15.05pp |
| 2003-12-31 | 69.52% | CA$18.11 Million ≈ $13.10 Million |
CA$26.05 Million ≈ $18.84 Million |
-- |
About Oncolytics Biotech Inc
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal aden… Read more